NEW YORK – Cubit Diagnostics announced on Tuesday that it has been awarded $2.6 million by the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx) Tech program. The funding will enable the Carlsbad, California-based startup to complete development of an assay to detect COVID-19, influenza A, and influenza B using its low-cost multimodal diagnostics system..

纽约——Cubit Diagnostics周二宣布，已获得美国国立卫生研究院快速加速诊断（RADx Tech）计划提供的260万美元资助。这笔资金将使这家位于加利福尼亚州卡尔斯巴德的初创公司能够完成其低成本多模式诊断系统的开发，用于检测COVID-19、甲型流感和乙型流感。

The RADx Tech funding, which was officially awarded on Dec. 2, 2024, allows the company to complete the development of its platform development, prepare its first assay for a clinical study, and reduce instrument and consumables costs to provide 'lab-quality results within 15 minutes at the point of care,' CubitDx CEO Kunal Sur said in a statement..

RADx Tech资金于2024年12月2日正式颁发，使公司能够完成其平台开发，准备其首个检测用于临床研究，并降低仪器和耗材成本，以“在护理点15分钟内提供实验室质量的结果”，CubitDx首席执行官Kunal Sur在一份声明中表示。

CubitDx is developing an integrated immunoassay and molecular diagnostic instrument incorporating ultra-fast PCR, proprietary sample purification, and low-cost microfluidics. The system, which is being developed in part in collaboration with Arete Biosciences, can assess up to eight targets in a single test and is intended for point-of-care use in physicians' offices and pharmacies.

CubitDx正在开发一种集成的免疫测定和分子诊断仪器，包含超快速PCR、专有样本纯化和低成本微流体技术。该系统部分与Arete Biosciences合作开发，可以在一次检测中评估多达八个目标，并计划用于医生办公室和药房的即时检测。

.

。

CubitDx was awarded $1.8 million by RADx for COVID/flu test development and platform feasibility in 2023, according to the website.

根据网站消息，CubitDx在2023年获得了RADx颁发的180万美元奖金，用于开发COVID/流感检测及平台可行性研究。

Evaluations of its COVID-19 assay last year at Emory University — home of

去年在埃默里大学对其COVID-19检测的评估——埃默里大学是

RADx's

RADx的

Independent Test Assessment Program (

独立测试评估计划（

ITAP

``` ITAP ```

) — showed it was more sensitive than standard rapid immunoassays and had equivalent sensitivity to high-throughput clinical lab tests, CubitDx said.

CubitDx表示，该测试比标准的快速免疫测定更为敏感，且与高通量临床实验室测试具有相当的灵敏度。

CubitDx is developing other tests for infectious diseases and global healthcare, including assays to detect sepsis, sexually transmitted infections, HIV, and human papillomavirus, the firm said.

CubitDx公司表示，他们正在开发其他用于传染病和全球医疗保健的检测方法，包括检测败血症、性传播感染、HIV和人乳头瘤病毒的检测试剂。